Axogen, Inc. (AXGN) Stock Price & Analysis
Axogen, Inc. (AXGN) fell 0.60% to USD 39.49 as of July 25, 2026 at 10:01 UTC, according to Nexqual real-time market data.
AXGN last closed at USD 39.73; the session ranged USD 39.35–40.65 on volume of 722,103 shares. Market capitalization is $2.10B, with a 52-week range of USD 12.39–46.95 (NCM). Source: Nexqual, July 25, 2026 at 10:01 UTC.
Key Statistics (as of July 25, 2026 at 10:01 UTC)
| Price | USD 39.49 |
|---|---|
| Change | ▼ 0.60% (down) |
| Previous Close | USD 39.73 |
| Open | USD 40.01 |
| Day Range | USD 39.35 – 40.65 |
| 52-Week Range | USD 12.39 – 46.95 |
| Volume | 722,103 shares |
| Market Cap | $2.10B |
| Exchange | NCM |
Technical Analysis (AXGN)
Nexqual's technical model rates AXGN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:01 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.49 (neutral) |
| vs SMA50 | Below (USD 41.99) |
| MACD | -0.95 (negative) |
Analyst Ratings (AXGN)
Wall Street analysts rate AXGN "None" based on 9 analysts, with a mean price target of USD 50.78 (range USD 48–55), per Nexqual as of July 25, 2026 at 10:01 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 50.78 |
| High Target | USD 55 |
| Low Target | USD 48 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (AXGN)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.12 |
| Revenue Estimate | $67.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est 0.07 ▼ miss |
| 2025-12-31 | USD 0.07 vs est 0.1 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.07 ▲ beat |
| 2025-06-30 | USD 0.12 vs est 0.06 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:01 UTC.
Financials & Fundamentals (AXGN)
| Total Revenue | $238.10M |
|---|---|
| Revenue Growth (YoY) | +26.60% |
| Gross Margin | +75.01% |
| Operating Margin | -4.61% |
| Profit Margin | -13.21% |
| ROE | -17.96% |
| Debt / Equity | 8.43 |
| Current Ratio | 7.1 |
| Total Cash | $101.60M |
| Total Debt | $20.64M |
| Free Cash Flow | $18.29M |
Source: Nexqual, July 25, 2026 at 10:01 UTC.
Financial Health Score (AXGN)
Nexqual rates Axogen, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 10:01 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -5% |
| Balance Sheet | Strong — $102M cash vs $21M debt, net cash position |
| Cash Flow | Solid — FCF $18M, 8% margin |
| Efficiency | Critical — ROE -18%, ROA -2.3% |
Ownership (AXGN)
| Insider Ownership | +2.19% |
|---|---|
| Institutional Ownership | +96.52% |
| Shares Outstanding | 53.18M |
| Float | 52.02M |
| Short % of Float | +11.85% |
Source: Nexqual, July 25, 2026 at 10:01 UTC.
Leadership (AXGN)
Axogen, Inc. is led by Michael D. Dale (age 65), President, CEO & Director, per Nexqual as of July 25, 2026 at 10:01 UTC.
| President, CEO & Director | Michael D. Dale (age 65) |
|---|---|
| Chief Financial Officer | Lindsey Hartley |
| Chief Marketing Officer | Jens Schroeder Kemp (age 48) |
| Vice President of Operations | Craig A. Swandal (age 64) |
| Vice President of Finance & Investor Relations | Harold D. Tamayo |
Major Backers & Investors (AXGN)
Notable institutional backers of Axogen, Inc. include First Light Asset Management, LLC, Morgan Stanley, ArrowMark Colorado Holdings LLC, according to Nexqual as of July 25, 2026 at 10:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 7.53% |
| Morgan Stanley | 5.87% |
| ArrowMark Colorado Holdings LLC | 3.6% |
| Polar Capital Holdings PLC | 2.82% |
| Artemis Investment Management Llp | 2.63% |
| FMR, LLC | 2.47% |
| Wasatch Advisors LP | 2.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.19% |
| Vanguard Group | 9.61% |
| Geode Capital | 2.29% |
Source: Nexqual, July 25, 2026 at 10:01 UTC.
From Axogen, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Biologics License Application Approval On December 3, 2025, the FDA approved the BLA for Avance as an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory nerve discontinuity (≤25mm).
- The Service Provider is a FDA registered tissue establishment and an AATB accredited organization.
- The Axogen Quality System meets the requirements set forth under 21 CFR Part 1271 for HCT/Ps, including Good Tissue Practices ("GTP") and is compliant with the 21 CFR Part 820 Quality System Regulation ("QSR").
- General We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
Partnerships
- We obtained certain economic development grants from state and local authorities totaling up to $2.7 million including $1.3 million of cash grants to offset costs to acquire and develop the APC Facility.
- In partnership with leading surgeons and healthcare providers, our team works to reverse legacy non-coverage policies for Avance Products and Axoguard products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
| BLFS | BioLife Solutions, Inc. | USD 29.98 | ▼ 3.76% |
| ANAB | AnaptysBio, Inc. | USD 54.15 | ▲ 2.93% |
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
| TCMD | Tactile Systems Technology, Inc | USD 27.48 | ▼ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:01 UTC. This page is informational and not investment advice.